Ericka M Ebot

9PUBLICATIONS
48CO-AUTHORS
Predictive and prognostic markersMolecular targetsHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Cell physiology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jul 30, 2024
Effectiveness of PARP Inhibitor Maintenance Therapy in Ovarian Cancer by BRCA1/2 and a Scar-Based HRD Signature in Real-World Practice.

Debra L Richardson, Julia C F Quintanilha, Natalie Danziger

|Nov 30, 2023
Evaluation of tissue- and plasma-derived tumor mutational burden (TMB) and genomic alterations of interest in CheckMate 848, a study of nivolumab combined with ipilimumab and nivolumab alone in patients with advanced or metastatic solid tumors with high TMB.

Jie He, Natallia Kalinava, Parul Doshi

|Sep 14, 2023
A pan-sarcoma landscape of telomeric content shows that alterations in RAD51B and GID4 are associated with higher telomeric content.

Radwa Sharaf, Dexter X Jin, John Grady

|Apr 16, 2023
Integrative Analysis of a Large Real-World Cohort of Small Cell Lung Cancer Identifies Distinct Genetic Subtypes and Insights into Histologic Transformation.

Smruthy Sivakumar, Jay A Moore, Meagan Montesion

|Sep 20, 2022
Transcriptomes of Prostate Cancer with TMPRSS2:ERG and Other ETS Fusions.

Konrad H Stopsack, Xiaofeng A Su, J Bailey Vaselkiv

|Jun 23, 2022
Deletions on 9p21 are associated with worse outcomes after anti-PD-1/PD-L1 monotherapy but not chemoimmunotherapy.

Ericka M Ebot, Daniel L Duncan, Khaled Tolba

Pageof 2

Frequent Collaborators

2 joint publications

Radwa Sharaf

2 joint publications

Garrett M Frampton

2 joint publications

Meagan Montesion

2 joint publications

Lorelei A Mucci